Caspofungin: all 46 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN TrialNot yet recruitingNCT07788586Phase 4
• CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis PneumoniaRecruitingNCT06892951Phase 1/2
• Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)TerminatedNCT01945281Phase 2Results posted
• Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell TransplantCompletedNCT01503515Phase 3Results posted
• Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid LeukemiaCompletedNCT01307579Phase 3Results posted
• A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)CompletedNCT01165320Phase 2Results posted
• Effect of Weight and/or Obesity on Caspofungin Drug ConcentrationsCompletedNCT01062165Phase 4Results posted
• Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)TerminatedNCT01045798Phase 2Results posted
• Comparison of Candida Eradication and Serum Cidal Activity of EchinocandinsCompletedNCT00839540Phase 4Results posted
• A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)CompletedNCT00717860Phase 3Results posted
• A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)CompletedNCT00635648Phase 3Results posted
• Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)CompletedNCT00520234Phase 4Results posted
• Caspofungin Maximum Tolerated Dose in Patients With Invasive AspergillosisCompletedNCT00404092Phase 2Results posted
• A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)CompletedNCT00250432Phase 3Results posted
• Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune SystemsTerminatedNCT00238355Phase 2Results posted
• Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCPStatus unknownNCT03978559Phase 4
• Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using CaspofunginCompletedNCT03857399Phase 2
• the Influence of Prophylactic and Empirical Anti-fungal Treatment in Severe Sepsis Patients With PerforationsCompletedNCT02941068Phase 2
• Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML PatientsWithdrawnNCT02856178Phase 1/2
• Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV PatientsStatus unknownNCT02603575Not applicable
• Evaluation of the Pharmacokinetics of Caspofungin in ICU PatientsCompletedNCT02596984Not applicable
• Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care UnitStatus unknownNCT02510053Not applicable
• Optimal Dosage of Caspofungin in Critically Ill PatientsCompletedNCT01994096Phase 4
• Pharmacokinetics of Caspofungin After One Dose in Patients With Liver FailureCompletedNCT01968395Phase 4
• Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary DiseaseStatus unknownNCT01499433Phase 4
• Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal ProphylaxisCompletedNCT01318148Phase 2
• Empirical Versus Preemptive Antifungal TherapyCompletedNCT01288378Phase 3
• Caspofungin as Prophylaxis in High Risk Liver Transplantation RecipientsStatus unknownNCT01260974Phase 2
• Pharmacokinetics of Caspofungin in Burn PatientsCompletedNCT00748345Phase 2/3
• Prophylaxis of Fungal Invasive Infections in LeukemiaCompletedNCT00501098Phase 2
• A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)CompletedNCT00379964Phase 3
• COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive AspergillosisCompletedNCT00334412Phase 4
• Prophylaxis With Caspofungin in High-Risk Liver TransplantationStatus unknownNCT00333645Phase 2
• Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)CompletedNCT00330395Phase 2
• Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)CompletedNCT00292071Phase 2
• A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell TransplantationCompletedNCT00148148Phase 2
• Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell TransplantCompletedNCT00110045Phase 2
• Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care UnitsCompletedNCT00099775Phase 3
• Caspofungin Study for Fungal Infections in Adults in Critical Care SettingsTerminatedNCT00095316Phase 3
• MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)CompletedNCT00082537Phase 2
• Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)CompletedNCT00082524Phase 2
• MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)CompletedNCT00076869Phase 2
• Caspofungin Acetate in Treating Children With Fever and NeutropeniaCompletedNCT00020527Not applicable
• Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer TreatmentCompletedNCT00008359Phase 3
• A Study of the Side Effects of L-743,872 in Men With Candidal EsophagitisCompletedNCT00005921Not applicable
• Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With FluconazoleTerminatedNCT00005920Phase 2

← Caspofungin overview